Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine ...

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.